Inactive Instrument

Highlights Vinings Holdings Inc. Other OTC

Equities

NDYN

US92744A1051

Highlights

Unlock all the news: Be the first to know and act before the market!

Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	26/02	CI
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	07/02	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	11/23/11	CI
Coeptis Therapeutics Holdings, Inc. Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics	17/23/17	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Coeptis Therapeutics Holdings, Inc Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic	01/23/01	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Coeptis Therapeutics Holdings, Inc. entered into a letter of intent to acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics, Inc.	18/23/18	CI
Coeptis Therapeutics Obtains Exclusive Rights to Negotiate to Acquire VyGen-Bio	29/23/29	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
Coeptis Therapeutics Holdings, Inc. Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program	31/23/31	CI
Coeptis Therapeutics Receives Non-Compliance Notice From Nasdaq	30/22/30	MT
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI
Coeptis Therapeutics, Inc. completed the acquisition of Bull Horn Holdings Corp. from Bull Horn Holdings sponsor LLC and others for approximately $170 million in a reverse merger transaction.	28/22/28	CI
Coeptis Therapeutics Inc. cancelled the acquisition of TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc..	22/22/22	CI
Coeptis Therapeutics, Inc. entered into a definitive agreement to acquire Bull Horn Holdings Corp. from Bull Horn Holdings sponsor LLC and others for approximately $180 million in a reverse merger transaction.	19/22/19	CI
Coeptis Therapeutics Inc. agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. for $6 million.	12/22/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vinings Holdings Inc. Other OTC

Equities

NDYN

US92744A1051

Highlights

Filters